Higher radiation dose for kidney cancer that has spread
Part of Cancer, Kidney & urinary, Women’s health & pregnancy clinical trials.
This trial tests whether giving a higher radiation dose to some tumors can help control kidney cancer that has spread to other parts of the body. It is for people who cannot have surgery to remove these tumors and are already receiving other treatments.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have kidney cancer that has spread beyond the kidney.
- Your tumors outside the skull cannot be removed by surgery or other procedures.
- You are 18 years or older.
- You are well enough to get around and care for yourself (Karnofsky score 50 or higher).
- Your blood counts, liver and kidney function are within acceptable ranges.
- You can undergo the required scans and follow-up visits.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests whether a precise, high-dose radiation treatment (SABR) can safely control kidney cancer that has spread to a few spots in the body. It may be an option if your cancer is progressing during treatment and your spots can be safely targeted with radiation.
This trial tests a combination of targeted radiation therapy with a restart of immunotherapy for people whose kidney cancer has grown after prior immunotherapy. It aims to see if radiation can help the immune system fight the cancer again.
This trial compares standard systemic therapy (medication) alone versus systemic therapy plus targeted radiation to the cancer spots for people with kidney cancer that has spread to a limited number of places (up to 5 spots). It aims to see if adding radiation helps control the cancer better.
This trial tests whether adding a special type of radiation to your current immunotherapy can help shrink kidney cancer tumors that have stopped responding or are stable. The goal is to see if the radiation can boost the immune system's ability to fight cancer elsewhere in the body.
This trial tests whether targeted, high-precision radiation (stereotactic radiotherapy) can control a small number of growing kidney cancer metastases while you continue systemic treatment. It may help people who have “oligoprogressive” disease, where only 1–3 spots are getting worse.
This trial tests whether adding radiation to standard drug therapy helps control kidney cancer that has spread to a few spots (oligometastatic). It is for people with clear cell renal cell carcinoma who have up to 5 metastases.
Hear when a new Renal Cell Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.